Abstract:Nimodipine is the primary clinical drug used to treat cerebral vasospasm following subarachnoid hemorrhage. Currently, tablets have low bioavailability when taken orally, and injections contain ethanol. Therefore, we investigated a new method of nimodipine administration, namely, nasoencephalic administration. Nasal administration of nimodipine was carried out by attaching the cell-penetrating peptide octa-arginine (R8) to liposomes of nimodipine and incorporating it into a temperature-sensitive in situ gel. The prepared liposomes and gels underwent separate evaluations for in vitro characterization. In vitro release exhibited a significant slow-release effect. In vitro toad maxillary cilia model, RPMI 2650 cytotoxicity, and in vivo SD rat pathological histotoxicity experiments showed that all the dosage from the groups had no significant toxicity to toad maxillary cilia, RPMI 2650 cells, and SD rat tissues and organs, and the cilia continued to oscillate up to 694 ± 10.15 min, with the survival rate of the cells being above 85%. A transwell nasal mucosa cell model and an isolated porcine nasal mucosa model were established, and the results showed that the osmolality of the R8-modified nimodipine liposomal gel to nasal mucosal cells and isolated porcine nasal mucosa was 30.41 ± 2.14 and 65.9 ± 7.34 μg/mL, respectively, which was significantly higher than that of the NM-Solution and PEGylated nimodipine liposome gel groups. Animal fluorescence imaging studies revealed that the R8-modified nimodipine liposomal gel displayed increased brain fluorescence intensity compared to the normal liposomal gel. Pharmacokinetic results showed that after transnasal administration, the AUC(0-∞) of the R8-modified nimodipine liposomal gel was 11.662 ± 1.97 μg·mL-1, which was significantly higher than that of the plain nimodipine liposomal gel (5.499 ± 2.89 μg·mL-1). Brain-targeting experiments showed that the brain-targeting efficiencies of the PEGylated nimodipine liposome gel and R8-modified PEGylated nimodipine liposome gels were 20.44 and 33.45, respectively, suggesting that R8/PEG/Lip-NM-TSG significantly increased the brain-targeting of the drug.

Study on Pharmacokinetics and Bioavailability of Nimodipine Nanostructured Lipid Carrier in Rats

Preparation and Characterization of Nimodipine-Loaded Nanostructured Lipid Systems for Enhanced Solubility and Bioavailability

Studies on the pharmacokinetics and relative bioavailability of nimodipine sustained release capsules in volunteers

Nimodipine Nanocrystals for Oral Bioavailability Improvement: Preparation, Characterization and Pharmacokinetic Studies.

Liquid Proliposomes of Nimodipine Drug Delivery System: Preparation, Characterization, and Pharmacokinetics

One-step Self-Assembled Nanomicelles for Improving the Oral Bioavailability of Nimodipine

Nimodipine nanocrystals for oral bioavailability improvement: role of mesenteric lymph transport in the oral absorption.

Study on the preparation of carboxymethyl chitosan-coated nimodipine nanoliposomes and their in vitro release

A Novel Drug Delivery Carrier Comprised of Nimodipine Drug Solution and a Nanoemulsion: Preparation, Characterization, in vitro, and in vivo Studies

Nimodipine-loaded mixed micelles: formulation, compatibility, pharmacokinetics, and vascular irritability study.

Study on in vivo distribution of nimodipine self-assembled preliposomes in mice using LC-MS

Intranasal lipid nanocapsules for systemic delivery of nimodipine into the brain: In vitro optimization and in vivo pharmacokinetic study

Distribution of Nimodipine in Brain Following Intranasal Administration in Rats

Preparation of Nimodipine-Loaded Microemulsion for Intranasal Delivery and Evaluation on the Targeting Efficiency to the Brain

Nimodipine Loaded Lipid Nanospheres Prepared by Solvent Diffusion Method in a Drug Saturated Aqueous System

Release Kinetics and in Vitro-in Vivo Correlation of Nimodipine Sustained-release Soft Gelatin Capsule

DETERMINATION OF NIMODIPINE AND ITS PHARMACOKINETICS IN HUMAN PLASMA BY CAPILLARY GAS CHROMATOGRAPHY USING ELECTRON-CAPTURE DETECTION

Octa-Arginine-Conjugated Liposomal Nimodipine Incorporated in a Temperature-Responsive Gel for Nasoencephalic Delivery

Development and Evaluation of High Bioavailable Sustained-Release Nimodipine Tablets Prepared with Monolithic Osmotic Pump Technology

Preparation and Characterization of Vinpocetine Loaded Nanostructured Lipid Carriers (NLC) for Improved Oral Bioavailability

Enhanced Pharmacokinetic Activity of Zotepine via Nanostructured Lipid Carrier System in Wistar Rats for Oral Application